Immune response to racotumomab in a child with relapsed neuroblastoma
Immunotherapy targeting ganglioside antigens is a powerful tool for the treatment of high risk neuroblastoma. However, only treatment with anti-GD2 antibodies has been used in clinical practice and other options may be pursued. We report the use of racotumomab, an anti-idiotype vaccine against N-gly...
Main Authors: | CLAUDIA VANESA SAMPOR, Marcelo David Guthmann, Alejandra eScursoni, Walter eCacciavillano, Ana eTorbidoni, Laura eGalluzzo, Sandra eCamarero, Jessica eLopez, Maria Teresa eGarcia de Davila, Leonardo eFainboim, Guillermo eChantada |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2012-12-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | http://journal.frontiersin.org/Journal/10.3389/fonc.2012.00195/full |
Similar Items
-
Anti-ganglioside antibodies induced in chickens by an alum-adsorbed anti-idiotype antibody targeting NeuGcGM3.
by: Marcelo David Guthmann, et al.
Published: (2013-01-01) -
Racotumomab therapeutic vaccine in an elderly with advanced lung cancer
by: Tatiana Hernández Casola, et al.
Published: (2020-03-01) -
Seguridad del Racotumomab en el tratamiento de pacientes con cáncer de pulmón de células no pequeñas
by: Leslie Pérez, et al.
Published: (2013-04-01) -
Cancer antigen prioritization: a road map to work in defining vaccines against specific targets. A point of view.
by: Daniel E Gomez, et al.
Published: (2012-06-01) -
Glioblastoma de células granulares supratentorial hemisférico. Presentación de caso y revisión de la literatura
by: María Teresa Solomón Cardona, et al.
Published: (2022-05-01)